Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value in non-core areas of its business. In October 2013, Merck announced a multi-year initiative to resource opportunities that offer the greatest potential return on investment, improve the company’s performance in the short term and create long-term value.
“We’re taking significant and decisive action to make Merck a more competitive company, better positioned to drive innovation and growth,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “We’re pleased with the solid progress we have already made against each of our key areas of focus, and we are quickly moving ahead to build on this momentum to make Merck a leaner, more agile company focused on the best opportunities to create value and advance global health.”
As part of the initiative announced last October, the company expects to realize a net reduction of annual operating expenses of approximately $2.5 billion by the end of 2015 with 40 percent, or $1.0 billion, to be realized by the end of 2014. These savings are off of the company’s full-year 2012 expense levels.
The company continues to make progress on its innovative pipeline and in 2014 expects to complete its regulatory application for MK-3475, the company’s anti-PD-1 immunotherapy, in patients with advanced melanoma who have previously been treated with ipilimumab ; as well as applications for odanacatib for osteoporosis; and suvorexant for insomnia. The company may also receive regulatory approvals for multiple promising candidates, including V503, the company’s 9-valent HPV vaccine candidate; vintafolide in the European Union for use in platinum-resistant ovarian cancer; vorapaxar for the reduction of atherothrombotic events when added to standard of care in patients with a history of heart attack and no history of stroke or transient ischemic attack; NOXAFIL IV for fungal infections; vaniprevir in Japan for the treatment of chronic hepatitis C virus (HCV) infection; and the allergy immunotherapies AIT-Grass and AIT-Ragweed.Core Markets and Commercial Therapeutic Area Focus The company has taken steps to significantly sharpen its focus on select core markets and commercial therapeutic areas. Progress since the October announcement includes:
- Increasing focus on the key markets of the United States, Japan, France, Germany, Canada, United Kingdom, China, Brazil, Russia and Korea.
- Intensifying its portfolio assessment process and recently announcing the divestiture of a portion of the company’s U.S. ophthalmics business and the sale of the U.S. marketing rights for SAPHRIS.
- Consistent with Merck’s new emphasis on its diabetes, acute hospital care, vaccines and oncology businesses, the company established its integrated oncology business unit and is recruiting external talent with deep scientific and commercial experience in oncology to promote Merck’s existing portfolio of products, as well as the future launch of MK-3475.
- Initiated the rolling submission of a BLA in the U.S. for MK-3475 in patients with advanced melanoma who have previously been treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. Merck expects to complete its application in the first half of 2014.
- Started additional MK-3475 clinical trials and now has 10 trials in more than 10 cancers, including a collaboration with GlaxoSmithKline to evaluate MK-3475 in combination with pazopanib in advanced renal cell carcinoma.
- Received Breakthrough Therapy designation for MK-5172/MK-8742, the company’s chronic HCV combination regimen, and advanced the combination into Phase IIB in a diverse range of chronic HCV patients.
- Filed vaniprevir (MK-7009), an investigational protease inhibitor for the treatment of chronic HCV infection, in Japan.
- Initiated Phase III trials for its BACE inhibitor for Alzheimer’s disease, MK-8931.
- Received priority review status for NOXAFIL IV.
- Plans to divest Sirna Therapeutics, Inc. to Alnylam.
- Exploring strategic options for its Animal Health and Consumer Care businesses to determine the most value-creating option for each and could reach different decisions about the two businesses. The company expects to complete the process and take action, if any, in 2014.
- Over the last four months of 2013, the company announced plans to close or sell manufacturing operations at Swords, Ireland; La Vallée, France; Arecibo and Barceloneta, Puerto Rico; and completed the sale of its active pharmaceutical ingredient (API) operations at Oss, the Netherlands; and announced closure of the Summit, N.J. site.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV